STOCKS TELEGRAPH

Tag: ARVN Stock

  • Arvinas (ARVN) Stock Rallies In Extended Session

    Arvinas (ARVN) Stock Rallies In Extended Session

    Arvinas, Inc. (NASDAQ: ARVN) shares experienced a notable rebound during after-hours trading on Wednesday, with shares climbing 6.48% to reach $24.00. This partial recovery came after ARVN had reported an 8.34% loss in regular trading hours, closing at $22.54. The positive movement was attributed to the release of encouraging preliminary clinical trial data that spurred investor optimism.

    Positive Results from the TACTIVE-U Study

    This week, Arvinas (ARVN) and Pfizer Inc. released encouraging first findings from the TACTIVE-U sub-study’s continuing Phase 1b component. The trial is investigating the use of vepdegestrant in combination with abemaciclib for patients with locally advanced or metastatic estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer. The information will be made public during the 2024 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas.

    Profile of Clinical Benefit and Safety

    Preliminary results from 16 patients demonstrated a tolerable safety profile for the combination of abemaciclib (150 mg twice daily) and the recommended Phase 3 dose of vepdegestrant (200 mg once daily).

    The combination therapy yielded a clinical benefit rate of 62.5%, which was observed in both ESR1-mutant and wild-type patients who had previously undergone treatment with a CDK4/6 inhibitor. These findings underline the potential of this combination treatment to provide significant benefits to patients who have limited options following prior treatments.

    Ongoing Evaluation and Future Prospects

    The feasibility of the combination was further supported by pharmacokinetic data, which showed no significant drug-drug interaction between vepdegestrant and abemaciclib. The safety profile was consistent with what has been previously observed in other clinical trials involving these drugs.

    The promising Phase 1b results set the stage for the Phase 2 portion of the study, which will continue to evaluate the combination of vepdegestrant and abemaciclib in post-CDK4/6 advanced breast cancer patients. Arvinas (ARVN) and Pfizer are also exploring additional combinations within the TACTIVE-U trial, which could offer new treatment avenues for metastatic breast cancer.

  • Arvinas, Inc. (ARVN) Stock on the Rise Following Global Partnership with Pfizer

    Arvinas, Inc. (ARVN) stock prices were up by 8.68% some time after market trading commenced on July 22nd, 2021, bringing the price per share up to USD$84.28 early on in the trading day.

    Partnership with Pfizer

    July 22nd, 2021 saw the company announce its global collaboration with Pfizer in order to develop and commercialize ARV-471, an investigational oral PROTAC, estrogen receptor protein degrader. The estrogen receptor has been shown to drive diseases in most cases and forms of breast cancer. The treatment is currently in Phase 2 dose expansion clinical trial, designed to treat patients with estrogen receptor (ER) positive/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-).

    Details of the Agreement

    As per the agreement, the partnering company will make an upfront payment of USD$650 million to ARVN, as well as a USD$350 million equity investment in the company. Global development costs, commercialization expenses, and profits will be split equally between the partnering companies. The combination of the company’s leadership in targeted protein degradation with Pfizer’s global capabilities and extensive expertise in breast cancer is expected to prove transformational.

    Scope of ARV-471

    This, in turn, will substantially enhance and accelerate the development and eventual commercialization of ARV-471 while concurrently advancing the company’s strategy of building a global and integrated biopharmaceutical company. Despite the advancement of the oncology space over recent years, there is still a sizeable unmet need that persists in the treatment of HR+ breast cancer. The partnership with Pfizer will see the deployment of PROTAC technology in a bid to help mitigate the devastation caused by the disease.

    ARV-471’s Potential

    December 2020 saw the company present interim data for its Phase 1 dose-escalation clinical trial of ARV-471 in patients with locally advanced or metastatic ER+/HER2- breast cancer. The treatment is indicated for its potential as a novel oral ER targeted therapy. Patients enrolled in the study were heavily pretreated, having been administered with cyclin-dependent kinase (CDK) 4/6 inhibitors. Despite the extensive pretreatment and the advanced stage of disease, the interim results demonstrated the treatment’s ability to promote substantial ER degradation and exhibits an encouraging clinical efficacy and tolerability profile.

    Future Outlook for ARVN Stock

    Armed with a massively expansive collaboration with Pfizer, the company is keen to make the most of the opportunities afforded to it as it expands and consolidates its market footprint. Current and potential investors are hopeful that management will be able to leverage the resources at their disposal to usher in organic growth over the long term.

  • Biotech Roundup: Nurse in New York City was first vaccinated against COVID-19

    Biotech Roundup: Nurse in New York City was first vaccinated against COVID-19

    As the U.S. reached 300,000 deaths connected with Covid-19, the first shots were given. The nurse in New York City was first vaccinated against COVID-19. On Monday, during the American mass vaccine drive, the first shot was rendered, which opened a new chapter in the fight against coronavirus’s pandemic.

    This week’s total number of shipments could exceed 2.9 million doses of Pfizer vaccine, which the FDA approved last Friday night for emergency use. A further 2.9 million supplies are eligible three weeks from now for recipients to receive a second dose.

    Phase 3 clinical trials found that the vaccine is 95 percent successful over a spectrum of age, ethnic and racial groups when administered in two doses. The first vaccination this week is obtained by front-line community staff and others who work with long-term care.

    BioCardia Inc. (NASDAQ:BCDA) shares were trading up 58.87% at $4.48 at the time of writing on Monday following the company reported that it has entered into definitive agreements with investors for the purchase and sale of 1,789,474 shares of its common stock at a purchase price of $4.75 per share in a registered direct offering priced at-the-market under Nasdaq rules.

    BioCardia Inc. (NASDAQ:BCDA) share price went from a low point around $1.91 to briefly over $6.75 in past 52 weeks, though shares have since pulled back to $4.48. BCDA market cap has remained high, hitting $60.84M at the time of writing, giving it price-to-sales ratio of more than 200.

    Rubius Therapeutics Inc. (RUBY) last closed at $8.73, in a 52-week range of $3.35 to $14.44. Analysts have a consensus price target of $10.67.

    AnPac Bio-Medical Science Co. Ltd. (ANPC) stock soar by 35.07% to $5.70 after reporting that it has made significant progress in detecting pre-cancer diseases.

    Synlogic Inc. (NASDAQ:SYBX) Shares headed rising, higher as much as 13.39% following the announcement of advancement of SYNB1891 to combination arm dosing with PD-L1 checkpoint inhibitor in the on-going phase 1 study for the treatment of solid tumors and lymphoma. The most recent rating by Oppenheimer, on August 21, 2019, is at a Perform.

    Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) rose 29.20% after gaining more than $35.33 on Monday.

    Arbutus Biopharma Corporation (ABUS) last closed at $4.88, in a 52-week range of $0.88 to $9.02. Analysts have a consensus price target of $6.40.

    Amarin Corporation plc (AMRN) stock soar by 1.60% to $5.09 after announcing the presentation of important VASCEPA® (icosapent ethyl)-related scientific findings during the National Lipid Association (NLA) Scientific Sessions 2020. The most recent rating by JP Morgan, on September 29, 2020, is at a Neutral.

    Arvinas Inc. (NASDAQ:ARVN) Shares headed rising, higher as much as 95.06% after revealing that it is commencing an underwritten public offering of $250.0 million of its common stock. The most recent rating by Oppenheimer, on December 14, 2020, is at an Outperform.

    BioLineRx Ltd. (NASDAQ:BLRX) rose 26.97% after gaining more than $0.72 on Monday. The company on November 23, 2020 reported its financial results for the quarter ended September 30, 2020.

    Homology Medicines Inc. (FIXX) last closed at $11.97, in a 52-week range of $8.70 to $22.50.

    BioCryst Pharmaceuticals Inc. (BCRX) stock soar by 4.68% to $8.50. The firm is presenting at the JMP Securities Hematology Summit, which is being conducted as a virtual event, on Tuesday, December 15, 2020 at 3:30 p.m. ET. The most recent rating by JP Morgan, on September 29, 2020, is at an Overweight.

    BioNTech SE (NASDAQ:BNTX) Shares headed falling, lower as much as -14.95% after the company and Pfizer Inc. (PFE) declared additional data on neutralizing antibody and T cell responses from the Phase 1/2 trial with BNT162b2 conducted in Germany. The most recent rating by BofA Securities, on December 01, 2020, is at a Neutral.

    Akebia Therapeutics Inc. (NASDAQ:AKBA) rose 10.80% after gaining more than $0.31 on Monday. The firm reported the latest scheduled program of AkebiaShares, a peer-to-peer educational series for the kidney community.

    Seelos Therapeutics Inc. (SEEL) last closed at $1.28, in a 52-week range of $0.42 to $1.71 after announcing the sale of a $12.0 million senior secured convertible note and shares of Seelos common stock to investors.

    VBI Vaccines Inc. (VBIV) stock soar by 6.71% to $3.34. The company recently revealed a partnership for the commercialization of VBI’s 3-antigen prophylactic hepatitis B (HBV) vaccine in the United States, Europe, and Canada, pending regulatory approvals. The most recent rating by Raymond James, on August 27, 2020, is at a Strong buy.